Publications
Filters: Keyword is Drug Therapy, Combination [Clear All Filters]
“Artemisinin Resistance and Stage Dependency of Parasite Clearance in Falciparum Malaria”, J Infect Dis, vol. 219, no. 9, pp. 1483-1489, 2019.
, “Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children”, Nat Commun, vol. 10, no. 1, p. 480, 2019.
, ,
“Antimalarial therapies in children from Papua New Guinea”, N Engl J Med, vol. 360, no. 12, p. 1254; author reply 1255, 2009.
, , “A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia”, Trop Med Int Health, vol. 12, no. 2, pp. 251-9, 2007.
, “World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs”, Malar J, vol. 6, p. 119, 2007.
, “Deployment of early diagnosis and mefloquine-artesunate treatment of falciparum malaria in Thailand: the Tak Malaria Initiative”, PLoS Med, vol. 3, no. 6, p. e183, 2006.
, “Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison”, Lancet, vol. 367, no. 9528, pp. 2075-85, 2006.
, “Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria”, Antimicrob Agents Chemother, vol. 50, no. 7, pp. 2281-5, 2006.
, “Malaria misconceptions”, Lancet, vol. 365, no. 9460, p. 653, 2005.
, “Pharmacokinetics of oral doxycycline during combination treatment of severe falciparum malaria”, Antimicrob Agents Chemother, vol. 49, no. 4, pp. 1622-5, 2005.
, “Artesunate combinations for treatment of malaria: meta-analysis”, Lancet, vol. 363, no. 9402. pp. 9-17, 2004.
, “Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil”, Clinical Infectious Diseases, vol. 35, no. 12, pp. 1498-504., 2002.
, “Drug resistant falciparum malaria: clinical consequences and strategies for prevention”, Drug Resistance Updates, vol. 4, no. 3, pp. 187-96., 2001.
, “Malaria epidemic in Burundi”, Lancet, vol. 357, no. 9261, pp. 1046-7., 2001.
, “A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria”, American Journal of Tropical Medicine and Hygiene, vol. 62, no. 1, pp. 65-9, 2000.
, “Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study”, Lancet, vol. 356, no. 9226, pp. 297-302, 2000.
, “Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria”, Antimicrob Agents Chemother, vol. 44, no. 3, pp. 697-704, 2000.
, “Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancy”, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 94, no. 6, pp. 689-93., 2000.
, “Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives”, American Journal of Tropical Medicine and Hygiene, vol. 60, no. 4, pp. 547-55, 1999.
, “No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine”, American Journal of Tropical Medicine and Hygiene, vol. 61, no. 6, pp. 964-7, 1999.
, “Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria”, Antimicrob Agents Chemother, vol. 43, no. 2, pp. 341-6, 1999.
, “Population pharmacokinetics of mefloquine in patients with acute falciparum malaria”, Clinical Pharmacology and Therapeutics, vol. 66, no. 5, pp. 472-84, 1999.
, “The Thai-Burmese border: drug studies of Plasmodium falciparum in pregnancy”, Annals of Tropical Medicine and Parasitology, vol. 93 Suppl 1, pp. S19-23., 1999.
, “Treatment of vivax malaria on the western border of Thailand”, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 93, no. 4, pp. 433-8, 1999.
, “Artesunate and mefloquine in the treatment of uncomplicated multidrug- resistant hyperparasitaemic falciparum malaria”, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 92, no. 2, pp. 207-11, 1998.
, “Use of artemisinin derivatives for the control of malaria”, Medecine Tropicale, vol. 58, no. 3, pp. 45-9, 1998.
, “Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria”, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 91, no. 5, pp. 574-7, 1997.
, “Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria”, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 89, no. 5, pp. 523-7, 1995.
, “New antimalarials. A risk-benefit analysis”, DRUG SAFETY, vol. 12, no. 4, pp. 264-73, 1995.
, “Oral artesunate in the treatment of uncomplicated hyperparasitemic falciparum malaria”, American Journal of Tropical Medicine and Hygiene, vol. 53, no. 5, pp. 522-5, 1995.
, “Single day mefloquine-artesunate combination in the treatment of multi- drug resistant falciparum malaria”, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 88, no. 2, pp. 213-7, 1994.
, “Treatment of multidrug-resistant Plasmodium falciparum malaria with 3- day artesunate-mefloquine combination”, Journal of Infectious Diseases, vol. 170, no. 4, pp. 971-7, 1994.
, “Malaria on the Thai-Burmese border: treatment of 5192 patients with mefloquine-sulfadoxine-pyrimethamine”, Bulletin of the World Health Organization, vol. 65, no. 6. pp. 891-6, 1987.
,